Abbott Laboratories Stock Price Targets

Comprehensive Price Target Analysis for Abbott Laboratories (ABT) As of 2025-10-03

Horizontal trendlines drawn (Low, Median, High targets)

Low Target: 122.00 (green) extended 30 days forward
Median Target: 143.12 (gray) extended 30 days forward
High Target: 159.00 (red) extended 30 days forward

Notes:

Timeframe extended 30 days beyond today: 2025-10-03 to 2025-11-02
Ticker: ABT
Colors used to distinguish levels:
- Low (support): #2E8B57
- Median (target): #808080
- High (resistance/target): #FF0000

Executive Summary

ABT sits in a defensive, high-quality healthcare franchise with robust margins and a solid balance sheet. The stock trades at a forward P/E of about 25.8x and a trailing P/E around 16.7x, with earnings quality supported by strong profit margins and a healthy cash position.
Analysts’ price targets imply a moderate upside to the near-term median target and a meaningful upside to the bull case, with a high target of 159.0. The Low target of 122.0 provides a downside risk reference.
Near-term catalysts include sustained revenue growth momentum, steady margins, and continued strong cash generation. Over the next 12–24 months, multiple expansion could accompany earnings growth, though broader macro risk and sector competition remain potential headwinds.

Fundamental Analysis Key Valuation & Financial Metrics

Current price: 132.99
Market cap: 231.46B
Enterprise value: 237.92B
Trailing P/E: 16.69
Forward P/E: 25.77
Peg ratio: not provided
Price/Book: 4.58
Return on equity (ROE): 30.93%
Return on assets (ROA): 6.62%
Profit margin: 32.43%
Gross margin: 56.32%
Operating margin: 19.73%
Debt to equity: 26.50x
Total cash: 7.28B
Total debt: 13.47B
Dividend yield: 1.77% (five-year avg: 1.70%)
Beta: 0.696 (defensive profile)

Table: Selected Fundamentals

Metric	Value
Current price	132.99
Market cap	231,463,649,280
Enterprise value	237,915,652,096
Trailing P/E	16.69
Forward P/E	25.77
Price to Book	4.58
ROE	30.93%
ROA	6.62%
Profit margin	32.43%
Gross margin	56.32%
Operating margin	19.73%
Debt/Equity	26.50x
Total cash	7.28B
Total debt	13.47B
Dividend yield	1.77%
5-year avg dividend yield	1.70%
Beta	0.696

Financial Health & Cash Flow

Balance sheet strength is solid: modest leverage (debt-to-equity ~26.5x) with a cash cushion and ongoing dividend.
Cash generation supports dividends and potential buybacks, which can be supportive for multiple expansion over time.

Earnings Analysis Recent Earnings Summary (Key highlights)

Revenue: Q2 2025 (2025-06-30) Total Revenue was 11.142B vs 10.358B (2025-03-31) and 10.974B (2024-12-31), indicating quarterly growth.
Gross Profit: 6.289B (2025-06-30) vs 5.890B (2025-03-31) and 6.032B (2024-12-31)
EBITDA: 3.048B (2025-06-30) vs 2.665B (2025-03-31)
Net Income (Continuing Ops): 1.779B (2025-06-30), 1.325B (2025-03-31), 9.229B (2024-12-31) — note the anomalously high 2024-12-31 Net Income that may reflect one-time items or discontinued operations
Diluted EPS (TTM snapshot from periods): 1.01 (2025-06-30), 0.76 (previous periods); 0.94 (2024-09-30), 0.74 (2024-06-30)
Basic EPS: 1.022 (2025-06-30), 0.76; 0.949 (2024-09-30), 0.748 (2024-06-30)
Reconciled depreciation and amortization: ~0.78B (consistent across periods)
R&D: ~0.725B (latest quarter) with SG&A around 3.091B

Notes on Normalized Earnings

Normalized EBITDA for the latest quarter: 3.037B
Normalized Income (per period) shows increases quarter-over-quarter (2025-03-31 to 2025-06-30) consistent with ongoing operating leverage.
There is an outlier Net Income figure in 2024-12-31 (9.229B) that warrants cautious interpretation; likely one-time items or adjustments impacting reported net income for that quarter.

EPS Trend

0q (most recent quarter): 1.29945
+1q: 1.49005
0y (year ago): 5.14295
+1y: 5.66911 Interpretation:
The trend shows a notable rise quarter-to-quarter in the latest periods (0q to +1q), with annual EPS (0y to +1y) indicating meaningful growth. The size of the year-ago numbers (5.14 to 5.67) suggests a healthy year-over-year improvement in the annualized EPS run rate.

EPS Revisions

0q: Up last 7 days = 1, Up last 30 days = 1, Down last 30 days = 0, Down last 7 days = 0
+1q: Up last 7 days = 21, Up last 30 days = 21, Down last 30 days = 1, Down last 7 days = 1
0y: Up last 7 days = 1, Up last 30 days = 1, Down last 30 days = 0, Down last 7 days = 0
+1y: Up last 7 days = 0, Up last 30 days = 0, Down last 30 days = 1, Down last 7 days = 1 Interpretation:
The +1q revisions show a noticeable tilt toward upgrades, suggesting analysts are modestly raising near-term earnings expectations. The +1y column indicates a few downgrades but not dominantly negative; overall sentiment remains cautiously constructive.

Technical Analysis Current Price Action

Price action around 133.0 in early Oct 2025, with price trading modestly above the 50-day moving average.

50-Day Moving Average (MA)

Latest 50-day MA values around 131.5–131.6, with price recently above the MA, indicating a mildly bullish short-term dynamic.

RSI (14)

Latest RSI values around 47.3 (mid-range, not yet indicating overbought or oversold extremes). This implies room for movement in either direction.

MACD (12,26,9)

MACD near 0.5 with a Signal around 0.7 as of the most recent data, suggesting modest bearish momentum in the near term, though the MACD histogram is small.

Analyst Consensus & Price Targets

Current price: 132.99
Target Low/Median/High (analyst consensus): 122.0 / 143.12 / 159.0
Number of analysts: 25
Target Mean: 142.88 Interpretation:
The median target sits at 143.12, implying a modest upside from here (~7.6% over current price). The mean target (~142.88) aligns with a similar upside profile. The high target of 159.0 suggests potential for meaningful upside if growth and multiples remain supportive. The Low target of 122.0 provides downside risk reference.

Price Target Analysis (Short, Mid, Long-Term)

Short-Term (3 months): Target 143.12 (median). Justification: constructive earnings revisions, solid revenue growth in the latest quarter, defensiveness of healthcare, and the stock trading near the 50-day MA with modest bullish momentum potential. Key drivers: continued margin stability, operating leverage, and non-cyclic demand in ABT’s broad product portfolio.
- Expected return vs. current price: approximately +7.6% (143.12 vs 132.99)
Mid-Term (12 months): Target 159.00 (high). Justification: potential multiple expansion as earnings stability persists, ongoing cash generation, potential buybacks, and favorable sector tailwinds. Key drivers: sustained margin expansion, continued cash flow strength, and favorable macro dynamics for healthcare staples.
- Expected return vs. current price: approximately +19.6% (159.00 vs 132.99)
Long-Term (3+ years): Target 122.00 (low). Justification: lower bound reflecting downside risk scenarios including macro headwinds, pharmaceutical/diagnostics competition, or slower-than-expected revenue growth; also a reference point for risk management. Key drivers: macro pressure, regulatory shifts, and competitive dynamics.
- Expected return vs. current price: approximately -8.3% (122.00 vs 132.99)

Table: Price Targets (Analyst Consensus vs. Levels)

Horizon	Target (Low/Median/High)	Implied Bias	Rationale / Key Drivers
Short-Term (3m)	Median 143.12	Up-side	Earnings revisions positive; near-term revenue momentum; valuation reasonable vs. defensives.
Mid-Term (12m)	High 159.00	Upside	Potential multiple expansion; strong cash flow; buyback potential; durable margins.
Long-Term (3+ yrs)	Low 122.00	Down-side	Macro/regulatory/competitive risk; downside protection reference.

Earnings Quality & Growth Snapshot

Revenue: Growing quarter-over-quarter (Q2 2025: 11.142B vs 10.358B prior quarter)
EBITDA: Up in the latest quarter (3.048B)
Net Income: Positive in most periods; notable outlier in 2024-12-31 (9.229B) likely one-time; normalizing view supports mid-term upside
EPS Trends: Positive near-term momentum with YoY uplift (0q 1.299, +1q 1.490; 0y 5.143; +1y 5.669)
Revisions: Net upgrades across +1q and 0q perspectives; overall constructive sentiment

Technical Indicators Summary

Price vs. 50-day MA: Price slightly above MA, suggesting a mild bullish tilt
RSI (mid-40s): Neutral area; no overt overbought/oversold pressure
MACD: Slight bearish momentum as of latest data but not extended; watch for a potential bullish cross if momentum improves

Key Risks & Opportunities

Key Risks:
- macroeconomic pressure on healthcare spending and payer dynamics
- competition in devices/pharma segments and pricing pressure
- any one-time items in quarterly results could distort earnings quality
Key Opportunities:
- strong cash generation enabling buybacks/dividends
- durable margins and diversified product portfolio
- potential upside from new product launches and acquisitions within Abbott’s core segments

Investment Recommendation

Recommendation: Hold
Time Horizon: 12–24 months
Rationale: The combination of solid fundamental backdrop, defensiveness, and a favorable but not exuberant multiple supports a constructive medium-term view. The near-term upside from the median target (~~7–8%) is reasonable, while the high target (~~+19–20%) reflects potential upside if earnings momentum and multiple expansion materialize. The low target provides a risk reference for downside scenarios.
Expected Return Potential (12–24 months): Approximately +7–20% on base-to-bull case depending on market conditions and execution of growth initiatives.

Price Target Levels (Display)

Horizontal trendlines (30 days forward) are drawn at:
- Low Target: 122.00 (green)
- Median Target: 143.12 (gray)
- High Target: 159.00 (red)

Reference Tables for All Data (Summary)

Analyst Targets | Current Price | Target Low | Target Median | Target High | Number of Analysts | Target Mean | |---:|---:|---:|---:|---:|---:| | 132.99 | 122.0 | 143.12 | 159.0 | 25 | 142.8848 |
Key Fundamentals | Metric | Value | |---:|---:| | Market Cap | 231.46B | | Enterprise Value | 237.92B | | Trailing P/E | 16.69 | | Forward P/E | 25.77 | | P/B | 4.58 | | ROE | 30.93% | | ROA | 6.62% | | Profit Margin | 32.43% | | Gross Margin | 56.32% | | Operating Margin | 19.73% | | Debt/Equity | 26.50x | | Total Cash | 7.28B | | Total Debt | 13.47B | | Dividend Yield | 1.77% | | Beta | 0.696 |
Earnings Summary (Key Periods) | Period | Total Revenue | Gross Profit | EBITDA | Net Income | Diluted EPS | Basic EPS | |---:|---:|---:|---:|---:|---:|---:| | 2025-06-30 | 11.142B | 6.289B | 3.048B | 1.779B | 1.01 | 1.022 | | 2025-03-31 | 10.358B | 5.890B | 2.665B | 1.325B | 0.76 | 0.76 | | 2024-12-31 | 10.974B | 6.032B | 2.973B | 9.229B | 5.27 | 5.329 | | 2024-09-30 | 10.635B | 5.937B | 2.872B | 1.646B | 0.94 | 0.949 | | 2024-06-30 | 10.377B | 5.774B | 2.552B | 1.302B | 0.74 | 0.748 |
EPS Trend | Period | Current | 7 days Ago | 30 days Ago | 60 days Ago | 90 days Ago | |---:|---:|---:|---:|---:|---:| | 0q | 1.29945 | 1.29945 | 1.29901 | 1.29901 | 1.33669 | | +1q | 1.49005 | 1.49005 | 1.49005 | 1.49005 | 1.46708 | | 0y | 5.14295 | 5.14295 | 5.14258 | 5.14258 | 5.15335 | | +1y | 5.66911 | 5.66874 | 5.66949 | 5.66949 | 5.67616 |
EPS Revisions | Period | UpLast7days | UpLast30days | DownLast30days | DownLast7Days | |---:|---:|---:|---:|---:| | 0q | 1 | 1 | 0 | 0 | | +1q | 21 | 21 | 1 | 1 | | 0y | 1 | 1 | 0 | 0 | | +1y | 0 | 0 | 1 | 1 |
Technical Indicators (Latest) | Indicator | Value (latest) | |---:|---:| | 50-day MA | ~131.5–131.6 (range observed in last 60 days) | | RSI (14) | ~47.3 (as of 2025-10-02) | | MACD (12,26,9) | MACD ~0.5; Signal ~0.7 (slightly negative momentum) |

Important caveats

The 2024-12-31 net income figure appears to be an outlier relative to other quarters; interpret with caution as it may reflect one-time items or discontinuations.
Forward-looking targets reflect consensus analyst estimates; actual performance may vary due to macro conditions, regulatory dynamics, and company-specific execution.

Epilogue

ABT remains a high-quality, dividend-backed healthcare name. The near-term path looks constructive with modest upside to the median target, while a bull scenario could push toward the high target if earnings momentum and cash returns unfold as anticipated. The downside risk, as captured by the low target, provides a realistic floor under bear-case scenarios. The drawn trendlines provide a clear visual reference for price interaction with the target levels over the coming month.